secwatch.observer — SEC 8-K summary
======================================

Issuer:     Autolus Therapeutics plc (AUTL)
CIK:        0001730463
Form:       8-K
Filed at:   2026-06-09T11:30:05+00:00
Accession:  0001730463-26-000069
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Autolus files UK annual report highlighting AUCATZYL launch, pipeline progress, and EU sales delay
--------------------------------------------------------------------------------

- AUCATZYL launched in US (Jan 2025) and UK (Jan 2026) for r/r B-ALL; conditional EU approval but no 2026 sales planned.
- Obe-cel paediatric r/r B-ALL Phase 1b showed 95% ORR; Phase 2 enrollment expected complete H1 2027.
- Obe-cel advanced to Phase 2 pivotal trial (LUMINA) for lupus nephritis; Phase 1 MS trial dosing started Oct 2025.
- Manufacturing site Nucleus in Stevenage, UK; Cardinal Health 105 as US distribution partner.
- AGM scheduled for June 29, 2026; ADS holders of record May 27, 2026 eligible to vote.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730463/000173046326000069/0001730463-26-000069-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730463/000173046326000069/autl-20260605.htm
  HTML page:      https://secwatch.observer/filing/0001730463-26-000069

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer